These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21036130)

  • 1. Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.
    Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
    Vaccine; 2010 Dec; 29(2):289-303. PubMed ID: 21036130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.
    Grosenbach DW; Jordan R; King DS; Berhanu A; Warren TK; Kirkwood-Watts DL; Tyavanagimatt S; Tan Y; Wilson RL; Jones KF; Hruby DE
    Vaccine; 2008 Feb; 26(7):933-46. PubMed ID: 18226434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
    Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
    Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host.
    Belyakov IM; Isakov D; Zhu Q; Dzutsev A; Klinman D; Berzofsky JA
    J Immunol; 2006 Nov; 177(9):6336-43. PubMed ID: 17056564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented With Acute Myeloid Leukemia After Smallpox Vaccination.
    Lindholm DA; Fisher RD; Montgomery JR; Davidson W; Yu PA; Yu YC; Burgado J; Wilkins K; Petersen BW; Okulicz JF
    Clin Infect Dis; 2019 Nov; 69(12):2205-2207. PubMed ID: 30959520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and humoral immunity against vaccinia virus infection of mice.
    Xu R; Johnson AJ; Liggitt D; Bevan MJ
    J Immunol; 2004 May; 172(10):6265-71. PubMed ID: 15128815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
    Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
    Antimicrob Agents Chemother; 2009 Dec; 53(12):4999-5009. PubMed ID: 19752270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.
    Zaitseva M; Shotwell E; Scott J; Cruz S; King LR; Manischewitz J; Diaz CG; Jordan RA; Grosenbach DW; Golding H
    J Virol; 2013 May; 87(10):5564-76. PubMed ID: 23468500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
    Perera LP; Waldmann TA; Mosca JD; Baldwin N; Berzofsky JA; Oh S
    J Virol; 2007 Aug; 81(16):8774-83. PubMed ID: 17553867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
    Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
    Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.
    Kremer M; Suezer Y; Volz A; Frenz T; Majzoub M; Hanschmann KM; Lehmann MH; Kalinke U; Sutter G
    PLoS Pathog; 2012; 8(3):e1002557. PubMed ID: 22396645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.
    Bissa M; Pacchioni SM; Zanotto C; De Giuli Morghen C; Illiano E; Granucci F; Zanoni I; Broggi A; Radaelli A
    Virus Res; 2013 Dec; 178(2):374-82. PubMed ID: 24050999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of protective T-cell antigens for smallpox vaccines.
    Ando J; Ngo MC; Ando M; Leen A; Rooney CM
    Cytotherapy; 2020 Nov; 22(11):642-652. PubMed ID: 32747299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
    Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine.
    Rock MT; Yoder SM; Talbot TR; Edwards KM; Crowe JE
    J Infect Dis; 2006 Aug; 194(4):435-43. PubMed ID: 16845626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.
    Meseda CA; Mayer AE; Kumar A; Garcia AD; Campbell J; Listrani P; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Clin Vaccine Immunol; 2009 Sep; 16(9):1261-71. PubMed ID: 19605597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel, killed-virus nasal vaccinia virus vaccine.
    Bielinska AU; Chepurnov AA; Landers JJ; Janczak KW; Chepurnova TS; Luker GD; Baker JR
    Clin Vaccine Immunol; 2008 Feb; 15(2):348-58. PubMed ID: 18057181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.